3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Lymphoid
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Melanoma
2
Colorectal Neoplasms
2
Advanced Solid Tumors
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor, Unspecified, Adult
1
Prostatic Neoplasms, Castration-Resistant
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Merkel Cell
1
Breast Neoplasms
1
Interventions
Cisplatin
90
Fluorouracil
76
Radiotherapy
63
Paclitaxel
58
Docetaxel
49
Oxaliplatin
48
Irinotecan
42
Leucovorin
32
Capecitabine
31
Carboplatin
27
Radiation
21
Surgical Procedures, Operative
20
Esophagectomy
20
pembrolizumab
15
Neoadjuvant Therapy
15
Bevacizumab
15
Cetuximab
13
Drug Therapy
12
Epirubicin
11
Chemotherapy, Adjuvant
9
S 1 (combination)
8
Magnetic Resonance Spectroscopy
8
Gemcitabine
8
Trastuzumab
7
Nivolumab
7
Erlotinib Hydrochloride
7
Surveys and Questionnaires
6
Panitumumab
6
Immunohistochemistry
6
Chemoradiotherapy
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Esophageal Neoplasms
×
zimberelimab
×
Clear all
NCT04772989
2025-08-28
ARC-12
Arcus Biosciences, Inc.
Phase 1
Completed
94 enrolled